Lyxumia® (lixisenatid) får europeiskt godkännande för behandling av typ 2-diabetes
Sanofi lanserar ny behandling: den första prandiella GLP-1 receptoragonisten, som tas en gång per dag i samband med måltid
Ämnen: Haelso-sjukvaard
-
-
Sanofi President, Global Operations, to retire
Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that Hanspeter Spek, President, Global Operations, will retire from his current role in mid-2013. A succession plan will be announced in due course.
-
Sanofi Compounds to be Featured in 178 Abstracts at American Society of Hematology Annual Meeting
Sanofi announced today that new research spanning the company’s marketed and investigational hematology products, including its late-stage selective JAK2 inhibitor, will be featured in 178 abstracts to be presented at the 2012 Annual Meeting of the American Society of Hematology in Atlanta, GA., December 8-11, 2012.
-
Sanofi Ranks Third on the Access to Medicine Foundation’s 2012 ATM Index
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index) created by the Access to Medicine Foundation, an international non-profit organization dedicated to improving access to medicine to societies in need.
-
Sanofi får positivt utlåtande från CHMP för Lyxumia® (lixisenatid) för behandling av vuxna med typ 2-diabetes
Sanofi meddelade idag att kommittén för humanläkemedel (CHMP) vid Europeiska läkemedelsmyndigheten (EMA) har utfärdat ett positivt yttrande där man rekommenderar godkännande av Lyxumia ® (lixisenatid) en gång dagligen för behandling av vuxna med typ 2-diabetes för att uppnå glykemisk kontroll i kombination med orala glukossänkande läkemedel och/eller basinsulin.
-
Sanofi and T1D Exchange to Launch Worldwide Study to Investigate Factors for Optimal Care for Young People with Diabetes
Sanofi and T1D Exchange, a non-profit organization focused on type 1 diabetes, announced today on World Diabetes Day that they will collaborate on the TEENs registry study. The aim of the study is to provide the type 1 diabetes community with a better understanding of how children, adolescents and young adults are currently living with type 1 diabetes.
-
Att leva med förmaksflimmer
Hjärt- och Lungsjukas Riksförbund har tillsammans med Sanofi producerat Flimmerrapporten som presenteras idag. Omkring 210 000 svenskar beräknas lida av förmaksflimmer. Risken att få sjukdomen ökar med åldern och var fjärde person över 40 år förväntas drabbas av förmaksflimmer någon gång i livet.
-
Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The Lancet
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the publication of results from the LEMTRADA™ (alemtuzumab) CARE-MS I and CARE-MS II pivotal studies in patients with relapsing-remitting multiple sclerosis (MS) in the November 1, 2012, online issue of The Lancet.
-
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine.
-
Genzyme Presents Second Phase III Study of Once-daily Oral AUBAGIO® (teriflunomide) Confirming Significant Impact on Disability
Sanofi and its subsidiary Genzyme announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
-
Genzyme to Present New Data from AUBAGIO® and LEMTRADATM Clinical Development Programs at ECTRIMS
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today new data from Genzyme’s clinical development programs for AUBAGIO® (teriflunomide) and LEMTRADA TM (alemtuzumab) will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10-13.
-
Journal of Clinical Oncology Publishes Phase III Results of ZALTRAP® (aflibercept) VELOUR Study in Previously Treated Metastatic Colorectal Cancer
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
-
New data from ORIGIN Shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population
Paris, France – October 5, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) today announced new results from the landmark ORIGIN trial showing treatment with Lantus® was approximately 3-fold more likely to achieve and maintain target glycemic levels, defined as HbA1C < 6.5% in this analysis, vs. standard care in individuals with pre-diabetes or early type 2 diabetes at high cardiovascular risk.
-
Sanofi Diabetes supports “Start Right, Eat Right” nutritional initiative
Sanofi Diabetes is funding “Start Right, Eat Right”, a public nutrition initiative taking place in Berlin, Germany, October 2nd - October 5th 2012. This event coincides with the 48th Annual Meeting of the European Association of the Study of Diabetes (EASD).
-
Sanofi to Acquire Genfar S.A., a Leader in Pharmaceutical Medicines in Colombia
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has signed an agreement to acquire Genfar S.A., a leading pharmaceuticals manufacturer headquartered in Bogota, Colombia. With this acquisition, Sanofi will become a market leader in Colombia and expand its portfolio of affordable pharmaceuticals in Latin America.
-
Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance Agreement
Sanofi (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) today announced they have restructured their successful long-term alliance following the loss of exclusivity of Plavix and Avapro/Avalide in many major markets.
-
Genzyme Phase 3 Study of Oral Compound Eliglustat Tartrate for Gaucher Disease Meets Primary Endpoint
Paris, France - October 2, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that ENGAGE, the first Phase 3 trial of its investigational oral therapy, eliglustat tartrate, in previously untreated patients with Gaucher disease type 1, met its primary endpoint.
-
Lyxumia® (lixisenatide)* in Combination with Basal Insulin plus Oral Anti-Diabetics Significantly Improved Glycemic Control
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced results from a study showing that the mechanism of action of once-daily Lyxumia® (lixisenatide) significantly delayed gastric emptying, a process accompanied by significant post-prandial glucose (PPG) lowering.
-
Sanofi and TB Alliance Announce Collaboration to Accelerate New Treatments Against Tuberculosis
Sanofi (EURONEXT: SAN and NYSE: SNY) and the Global Alliance for TB Drug Development (TB Alliance) announced today a new research collaboration agreement to accelerate the discovery and development of novel compounds against tuberculosis (TB), a deadly infectious disease that resulted in almost 1.5 million deaths worldwide1 in 2010.
-
FDA Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Multiple Sclerosis
Paris, France – September 12, 2012 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO® (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).
Visa mer
Loading...